Proficio Capital Partners LLC Purchases Shares of 11,285 Schrödinger, Inc. (NASDAQ:SDGR)

Proficio Capital Partners LLC purchased a new stake in Schrödinger, Inc. (NASDAQ:SDGR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,285 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Avanza Fonder AB acquired a new stake in shares of Schrödinger in the 4th quarter valued at about $577,000. Barclays PLC raised its stake in shares of Schrödinger by 421.6% in the 3rd quarter. Barclays PLC now owns 107,554 shares of the company’s stock valued at $1,995,000 after purchasing an additional 86,933 shares during the period. State Street Corp raised its stake in shares of Schrödinger by 1.8% in the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company’s stock valued at $39,987,000 after purchasing an additional 38,972 shares during the period. Quest Partners LLC raised its stake in shares of Schrödinger by 861.0% in the 3rd quarter. Quest Partners LLC now owns 43,773 shares of the company’s stock valued at $812,000 after purchasing an additional 39,218 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Schrödinger by 1.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,191,054 shares of the company’s stock valued at $40,644,000 after purchasing an additional 29,920 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Stock Performance

Schrödinger stock opened at $21.66 on Wednesday. Schrödinger, Inc. has a 52 week low of $16.67 and a 52 week high of $29.15. The stock has a market capitalization of $1.58 billion, a P/E ratio of -9.26 and a beta of 1.62. The stock has a 50-day simple moving average of $22.55 and a 200 day simple moving average of $20.66.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business had revenue of $88.32 million for the quarter, compared to the consensus estimate of $83.20 million. Research analysts forecast that Schrödinger, Inc. will post -2.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SDGR. BMO Capital Markets lifted their price target on Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. KeyCorp raised their price objective on Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Piper Sandler decreased their price objective on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $32.29.

Insider Buying and Selling

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the completion of the sale, the chief financial officer now directly owns 27,544 shares in the company, valued at $599,357.44. This trade represents a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 8.60% of the stock is currently owned by corporate insiders.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.